John A.orwin

Biography

 Mr. Orwin has served as a member of our Board of Directors since November 2012. Mr. Orwin has served as the chief executive officer of Relypsa since May 2013. Previously he was the chief executive officer at Affymax since 2011, after joining the company in 2010 as its chief operating officer. He held leadership roles in marketing, sales, and operations for major pharmaceutical companies including Genentech, Johnson & Johnson, Alza Pharmaceuticals, Rhone-Poulenc Rorer, and Schering-Plough Corporation. Mr. Orwin brings a track record of substantial accomplishment in the pharmaceutical industry to Array’s board of directors. Over his career, Mr. Orwin has built successful businesses and commercialized a range of blockbuster products. Most recently, he led the approval and launch of Omontys®, a hematology product for the treatment of anemia in chronic kidney disease. Prior to joining Affymax, he led Genentech’s BioOncology business unit and grew a portfolio of cancer-fighting products including Avastin®, Rituxan®, Herceptin® and Tarceva® to over $7 billion in U.S. sales. Earlier in his career, he was responsible for the successful launch of Taxotere®, exceeding budget and forecast expectations. Mr. Orwin is currently chairman of the board of Affymax and a member of the board of directors of Relypsa and Retrophin, Inc.

Research Interest

 Mr. Orwin has served as a member of our Board of Directors since November 2012. Mr. Orwin has served as the chief executive officer of Relypsa since May 2013. Previously he was the chief executive officer at Affymax since 2011, after joining the company in 2010 as its chief operating officer. He held leadership roles in marketing, sales, and operations for major pharmaceutical companies including Genentech, Johnson & Johnson, Alza Pharmaceuticals, Rhone-Poulenc Rorer, and Schering-Plough Corporation. Mr. Orwin brings a track record of substantial accomplishment in the pharmaceutical industry to Array’s board of directors. Over his career, Mr. Orwin has built successful businesses and commercialized a range of blockbuster products. Most recently, he led the approval and launch of Omontys®, a hematology product for the treatment of anemia in chronic kidney disease. Prior to joining Affymax, he led Genentech’s BioOncology business unit and grew a portfolio of cancer-fighting products including Avastin®, Rituxan®, Herceptin® and Tarceva® to over $7 billion in U.S. sales. Earlier in his career, he was responsible for the successful launch of Taxotere®, exceeding budget and forecast expectations. Mr. Orwin is currently chairman of the board of Affymax and a member of the board of directors of Relypsa and Retrophin, Inc.